Gilead Sciences, Inc. is a major player in the Healthcare sector, specifically within the Drug Manufacturers industry. As a biopharmaceutical company, it focuses on discovering, developing, and commercializing innovative medicines. With a substantial market capitalization of 157.96 Billion USD, Gilead holds a significant position in the global market, known primarily for its treatments for HIV/AIDS, liver diseases, and cancer.

Based on our proprietary technical scoring system, Gilead Sciences, Inc. currently receives a "Sell" rating with a total score of -2. The primary driver for this negative outlook is the long-term trend indicator; the current price of $127.23 is trading below its 200-day simple moving average ($127.65), contributing a score of -2. This bearish signal is further reinforced by the MACD histogram, which is negative, indicating downward momentum and subtracting 1 point. In contrast, the trend strength is weak (ADX at 17.63) and the RSI (46.73) is in neutral territory, both yielding 0 points. A single positive signal comes from the On-Balance Volume (OBV), which is above its short-term average, suggesting some recent accumulation and adding 1 point.

In conclusion, the technical "Sell" rating suggests a cautious short-term outlook. This technical perspective presents a mixed picture when compared to the company's fundamentals. The P/E ratio of 17.31 appears reasonable, and the company reports an exceptionally high dividend yield of 258.0. However, specific data on the last reported earnings per share (EPS) is currently unavailable. Investors should note that the next earnings report is scheduled for on 06/08/2026, which will be a key event to watch for any potential shifts in the company's financial trajectory. The current bearish technical signals warrant caution, despite some seemingly attractive fundamental metrics.